EUVIMEDEUVIMED entdecken
Crossref

Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy

Jing Liu iD, Zhihao Zhao, Richard Zanni, Xiaomin Jiang iD, Ralph R Weichselbaum, Wenbin Lin iD

ACS Nano · 2025

DOI: 10.1021/acsnano.4c16542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Jing Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, United States. Hauptthemen laut MEDLINE: Immunotherapy, Nanoparticles, Immune Checkpoint Inhibitors, Toll-Like Receptor 3. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual blockade of CD47 and PD-L1 immune checkpoints has shown potential in cancer treatment, but its clinical application is hindered by the on-target off-tumor immunotoxicities of monoclonal antibodies. Herein, we report a core-shell nanoparticle, PPA/HG, comprising polyinosinic: polycytidylic acid (PPA) in the core and a cholesterol-conjugated prodrug of 3-(hydroxyolinoyl)glycine (HG) on the shell, for potent cancer immunotherapy. PPA/HG shows a long half-life in the bloodstream to efficiently accumulate in tumors, where PPA/HG rapidly releases HG and PPA. HG inhibits the histone lysine demethylase 3A/c-Myc transduction for effective CD47 and PD-L1 downregulation in cancer cells while PPA activates toll-like receptor 3 in dendritic cells and tumor-associated macrophages to promote dendritic cell maturation and macrophage repolarization. PPA/HG promotes the infiltration and activation of effector T lymphocytes, meanwhile decreasing the population of immunosuppressive regulatory T cells. Systemic administration of PPA/HG significantly inhibits the progression of orthotopic triple-negative breast cancer and pancreatic ductal adenocarcinoma with minimal side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNanoparticlesImmune Checkpoint InhibitorsToll-Like Receptor 3AnimalsHumansMiceCell Line, TumorDown-RegulationFemaleB7-H1 AntigenPoly I-C

Stichwörter der Autor:innen

cancer immunotherapycluster of differentiation 47histone lysine demethylase 3Ananoscale coordination polymerprogrammed cell death-ligand 1toll-like receptor 3

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenToll-Like Receptor 3Poly I-C

Autor:innen und Institutionen

  • Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, United States.
  • Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, 5758 South Maryland Avenue, Chicago, Illinois 60637, United States.

ORCID-Profile: Jing Liu, Xiaomin Jiang, Wenbin Lin

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Liu, J., Zhao, Z., Zanni, R., Jiang, X., Weichselbaum, R. R., & Lin, W. (2025). Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy. ACS Nano. https://doi.org/10.1021/acsnano.4c16542

Vancouver

Liu J, Zhao Z, Zanni R, Jiang X, Weichselbaum RR, Lin W. Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy. ACS Nano. 2025. doi:10.1021/acsnano.4c16542

BibTeX
@article{Liu2025,
  author = {Liu, Jing and Zhao, Zhihao and Zanni, Richard and Jiang, Xiaomin and Weichselbaum, Ralph R and Lin, Wenbin},
  title = {Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy},
  journal = {ACS Nano},
  year = {2025},
  doi = {10.1021/acsnano.4c16542}
}
Kostenlos starten →